Company newsCompany release

Johnson & Johnson JNJ

Johnson & Johnson presents new patient experience data on nipocalimab in Sjögren's disease

Among 49 DAHLIAS participants interviewed, mouth dryness was the symptom most often reported and, among those asked, most often prioritized for improvement, the company said.

GetSignal 

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Johnson & Johnson said on November 7, 2026 that it has new patient experience findings from the Phase 2 DAHLIAS study of nipocalimab in Sjögren's disease. The company said the results show mouth dryness is the symptom improvement that matters most to patients. The findings complement previously reported Phase 2 results, in which an at least 50% increase in saliva production from baseline was seen at Week 24 in 33% of patients on the high-dose 15 mg/kg nipocalimab group, versus 16% on placebo.

Johnson & Johnson said 96% of patients surveyed cited mouth dryness, the most frequently reported symptom. Other core symptoms reported were fatigue (92%), eye dryness (90%), joint pain (73%) and, among women, vaginal dryness (49%). The company said patients who took part in the interviews reported improvements across many of these symptoms during the treatment phase.

The company said the findings helped inform the design of the ongoing Phase 3 study of nipocalimab in Sjögren's disease. The data are among 23 abstracts on nipocalimab to be presented at the American College of Rheumatology Convergence 2026. Johnson & Johnson initiated the Phase 3 DAFFODIL study in adults with moderate-to-severe disease after the Phase 2 results.

Key facts

Interviewed patients citing mouth dryness
96% of 49 participants interviewed
Interviewed patients citing fatigue
92% of 49 participants interviewed
Phase 2 study
DAHLIAS, 163 participants
Conference
American College of Rheumatology Convergence 2026

All JNJ news

Source: The company's release on PR Newswire, November 7, 2026.

Written by GetSignal with AI from the company's press release. How we make news

Not investment advice.

More company news

Johnson & Johnson first, then the newest

All company news